Acadia Pharmaceuticals (ACAD) Other Non-Current Liabilities (2010 - 2026)
Acadia Pharmaceuticals (ACAD) posted quarterly Other Non-Current Liabilities of $12.6 million for Q1 2026, down 36.7% year-over-year from $20.0 million in Q1 2025, and down 33.97% quarter-over-quarter from $19.1 million in Q4 2025.
Acadia Pharmaceuticals (ACAD) Other Non-Current Liabilities (2010 - 2026) Analysis & Trends
Acadia Pharmaceuticals' Other Non-Current Liabilities history runs 11 years deep, the most recent figure standing at $12.6 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities fell 36.7% year-over-year to $12.6 million; the TTM figure through Mar 2026 stood at $12.6 million (down 36.7% YoY), while the FY2025 annual figure was $19.1 million, up 5.99% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $12.6 million, down from $19.1 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $28.5 million in Q2 2025, with the low at $200000.0 in Q1 2024.
- The 5-year median for Other Non-Current Liabilities is $12.6 million (2026), against an average of $12.2 million.
- The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities tumbled 96.23% in 2024, then soared 9881.5% in 2025.
- Acadia Pharmaceuticals' Other Non-Current Liabilities stood at $9.1 million in 2022, then soared by 66.93% to $15.1 million in 2023, then advanced by 19.21% to $18.1 million in 2024, then advanced by 5.99% to $19.1 million in 2025, then sank by 33.97% to $12.6 million in 2026.
- Business Quant data shows ACAD's Other Non-Current Liabilities at $12.6 million in Q1 2026, $19.1 million in Q4 2025, and $13.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.31 Mn |
| Mar 31, 2026 | 12.64 Mn |
| Dec 31, 2025 | 19.14 Mn |
| Sep 30, 2025 | 13.89 Mn |
| Jun 30, 2025 | 28.55 Mn |
| Mar 31, 2025 | 19.96 Mn |
| Dec 31, 2024 | 18.06 Mn |
| Sep 30, 2024 | 15.32 Mn |
| Jun 30, 2024 | 12.36 Mn |
| Mar 31, 2024 | 200,000.00 |
| Dec 31, 2023 | 15.15 Mn |
| Sep 30, 2023 | 12.66 Mn |
| Jun 30, 2023 | 9.26 Mn |
| Mar 31, 2023 | 5.31 Mn |
| Dec 31, 2022 | 9.07 Mn |
| Sep 30, 2022 | 6.47 Mn |
| Jun 30, 2022 | 5.54 Mn |
| Mar 31, 2022 | 4.37 Mn |
| Dec 31, 2021 | 603,000.00 |
| Sep 30, 2021 | 4.82 Mn |